Detection of anti-recombinant beta(2)-glycoprotein 1 and anti-recombinant beta(2)-glycoprotein 1 fifth-domain antibodies in sera from patients with systemic lupus erythematosus

作者：Yang, CD^*; Chen, SL; Shen, N; Qi, M; Xue, F

来源：Rheumatology International, 1998, 18(1): 5-10.

• beta(2)-glycoprotein 1
• anticardiolipin antibody
• systemic lupus erythematosus

Two kinds of plasmid expression vectors which expressed beta(2)-glycoprotein 1(beta(2)GP1) and the fifth domain of beta(2)-glycoprotein 1 (beta(2)GP1-D5) were constructed respectively in this study. The antigenicity of recombinant beta(2)GP1 (r beta(2)GP1) and beta(2)GP1-D5 (r beta(2)GP1-D5) was identified by immunoblots using rabbit anti-beta(2)GP1 antibodies, and the recombinant proteins were purified. Both anti-r beta(2)GP1 and anti-beta(2)GP1-D5 antibodies in 112 patients were detected by ELISA using r beta(2)GP1 and r beta(2)GP1-D5 as coating antigens. A significant statistical correlation (r=0.667, P<0.01) between the levels of anti-beta(2)GP1 and anticardiolipin (ACL) antibodies was found. The presence of anti-r beta(2)GP1 antibodies was associated with an increased frequency of history of thrombosis and/or recurrent abortion; hence anti-r beta(2)GP1 1 assay provided better specificity than conventional ACL assay. Detection of anti-r beta(2)GP1 antibodies may be of potential value in evaluating the risk of thrombosis and/or symptoms associated with other antiphospholipid syndromes (APS). The binding of anti-r beta(2)GP1 from the sera of patients with APS to r beta(2)GP1 was inhibited by r beta(2)GP1-D5. Meanwhile, of 28 patients who had positive anti-r beta(2)GP1 antibodies in sera, 27 (96.4%) had positive anti-r beta(2)GP1-D1 antibodies. This indicated that the antigenic epitope of beta(2)GP1 may be located in its fifth domain.

• 出版日期1998-6
• 单位南京大学